How big is MannKind Corp.?

As of Jun 18, MannKind Corp. has a market capitalization of 1,139.75 million, with net sales of 297.60 million and a net profit of 30.12 million over the last four quarters. Shareholder's funds are at -78.82 million, and total assets amount to 393.84 million.

As of Jun 18, MannKind Corp. has a market capitalization of 1,139.75 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 297.60 million, while the sum of net profit for the same period is 30.12 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -78.82 million and total assets amounting to 393.84 million.

What does MannKind Corp. do?

MannKind Corporation is a biopharmaceutical company that develops inhaled therapies for diabetes and orphan lung diseases. As of March 2025, it reported net sales of $78 million and a net profit of $13 million, with a market cap of approximately $1.14 billion.

Overview:<BR>MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Net Sales: 78 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 13 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 1,139.75 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 26.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.26<BR>- Return on Equity: -86.13%<BR>- Price to Book: -19.44<BR><BR>Contact Details:<BR>- Address: 30930 Russell Ranch Rd Ste 300, WESTLAKE VILLAGE CA: 91362-7379<BR>- Tel: 1 818 6615000<BR>- Website: http://www.mannkindcorp.com

Should I buy, sell or hold MannKind Corp.?

Who are in the management team of MannKind Corp.?

As of March 2022, the management team of MannKind Corp. includes Dr. James Shannon (Chairman), Dr. Michael Castagna (CEO), Dr. Sabrina Kay, Mr. Kent Kresa, Mr. Ronald Consiglio, Dr. Michael Friedman, and Ms. Jennifer Grancio. They oversee the company's strategic direction and operations.

As of March 2022, the management team of MannKind Corp. includes the following individuals:<BR><BR>- Dr. James Shannon, Chairman of the Board<BR>- Dr. Michael Castagna, Chief Executive Officer and Director<BR>- Dr. Sabrina Kay, Director<BR>- Mr. Kent Kresa, Director<BR>- Mr. Ronald Consiglio, Independent Director<BR>- Dr. Michael Friedman, Independent Director<BR>- Ms. Jennifer Grancio, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is MannKind Corp. overvalued or undervalued?

As of November 9, 2016, MannKind Corp. is classified as risky and overvalued, with a P/E ratio of 26, an EV to EBITDA of 13.61, and a PEG ratio of 0.06, significantly higher than its peers, despite a strong 5-year return of 169.71% that has recently underperformed the S&P 500.

As of 9 November 2016, MannKind Corp. moved from does not qualify to risky. The company is currently overvalued based on its valuation metrics. Key ratios include a P/E ratio of 26, an EV to EBITDA of 13.61, and a PEG ratio of 0.06, which suggests a significant discrepancy in growth expectations relative to its price. <BR><BR>In comparison to peers, MannKind Corp. has a P/E ratio of 38.35, which is notably higher than Catalyst Pharmaceuticals, Inc. at 12.14, indicating that MannKind may be overvalued despite its risky classification. Additionally, while MannKind's 5-year return of 169.71% outperformed the S&P 500's 96.61%, its year-to-date return of -12.75% underperformed against the S&P 500's 12.22%, reinforcing the notion of overvaluation in the current market context.

Is MannKind Corp. technically bullish or bearish?

As of October 3, 2025, MannKind Corp. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 year-to-date and over the past year, but achieving a strong 5-year return of 216.20%.

As of 3 October 2025, the technical trend for MannKind Corp. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the monthly MACD is mildly bearish. Bollinger Bands indicate a mildly bullish stance on the weekly and bullish on the monthly. However, daily moving averages are mildly bearish, and both the KST and Dow Theory show mixed signals with no clear trend. <BR><BR>In terms of performance, MannKind has underperformed against the S&P 500 year-to-date and over the past year, with returns of -11.98% and -12.79%, respectively, compared to the S&P 500's 14.18% and 17.82%. Over longer periods, the stock has performed better, with a 5-year return of 216.20% versus the S&P 500's 100.56%.